Preferences help
enabled [disable] Abstract
Number of results
2019 | 6 | 1 | 26-29
Article title

Nowe trendy w farmakoterapii jaskry

Title variants
New trends in glaucoma pharmacotherapy
Languages of publication
Pomimo licznych metod leczenia jaskry nadal nie potrafimy wpływać na wszystkie przyczyny jej powstawania. Dlatego badane są liczne substancje o różnych mechanizmach działania. W ostatnim czasie zostały wprowadzone do lecznictwa 3 leki: cytykolina, netarsudil i latanoprost bunod, które zostaną omówione w tym artykule.
Despite many methods of treating glaucoma, we still cannot affect all causes of this disease. Therefore, many substances with different mechanisms of action are investigated. Recently, 3 drugs have been introduced to the treatment: citicoline, netarsudil and latanoprost bunod, which will be discussed in this article
Physical description
  • Katedra i Zakład Farmakologii, Uniwersytet Medyczny we Wrocławiu
  • 1. Yang X, Zeng Q, Goktas E, et al. T-Lymphocyte Subset Distribution and Activity in Patients with Glaucoma. Invest Ophthalmol Vis Sci 2019; 60(4): 877-888.
  • 2. Bucolo C, Platania CBM, Drago F, et al. Novel Therapeutics in Glaucoma Management. Curr Neuropharmacol 2018; 16(7): 978-992.
  • 3. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom 2019. DOI: 10.1111/cxo.12853. [Epub ahead of print].
  • 4. Khouri AS, Serle JB, Bacharach J, et al. Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol 2019. [Epub ahead of print].
  • 5. Kahook MY, Serle JB, Mach FS, et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution. Am J Ophthalmol 2019. DOI: 10.1016/j.ajo.2019.01.003. [Epub ahead of print].
  • 6. You Y, Joseph C, Wang C, et al. Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain 2019; 142(2): 426-442.
  • 7. Boyd ZS, Kriatchko A, Yang J, et al. Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci 2003; 44(12): 5206-5211.
  • 8. Schmidl D, Schmetterer L, Garhöfer G, et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther 2015; 31(2): 63-77.
  • 9. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther 2002; 5(6): 780-787.
  • 10. Tomita H., Nakazawa T, Sugano E, et al. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol 2002; 452(3): 263-268.
  • 11. Tsai JC, Song BJ, Wu Let, et al. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007; 16(6): 567-571.
  • 12. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002; 70(2): 133-139.
  • 13. Parisi V, Oddone F, Ziccardi L, et al. Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function. Curr Neuropharmacol 2018; 16(7): 919-932.
  • 14. Parisi V, Oddone F, Roberti G. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther 2019. DOI: 10.1007/s12325-019-0897-z. [Epub ahead of print].
  • 15. Adams CM, Stacy R, Rangaswamy N, et al. Glaucoma – Next Generation Therapeutics: Impossible to Possible. Pharm Res 2018; 36(2): 25.
  • 16. Dillinger AE, Guter M, Froemel F, et al. Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy. Small 2018; 14(50): e1803239.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.